Panel Discussion

May 17, 2018

The Genetics Informatics Trial (GIFT) examined the potential benefits of using genotype information to personalize the dosing of warfarin therapy in patients undergoing elective hip or knee replacement surgery.  Previous trials have not consistently shown that genotype-guided warfarin dosing is beneficial.  Dr. Paul Solinsky reviews the methods and results of the GIFT Trial and our panelists, Dr. Daniel Witt and Dr. Edith Nutescu, discuss the study implications.


To earn...

Comments: 0
May 19, 2017

A recent study evaluated the use of fish oil (EPA/DHA) supplementation during the 3rd trimester of pregnancy to prevent the development of wheezing and asthma in children.  Does it work?  Who should receive fish oil supplementation during pregnancy?  Watch this vidcast and find out!


Comments: 0
May 16, 2016

Patients who've had an ischemic stroke or transient ischemic attack (TIA) are at very high risk for recurrent vascular events. The current standard of care is to address cardiovascular risk factors. The Insulin Resistance Intervention after Stroke (IRIS) trial examined the benefits and risks of pioglitazone use after a recent ischemic stroke or TIA. In this video the methodology and results of the IRIS study are presented and our panelists discuss the strengths, weakness, and clinical...

Comments: 0
May 4, 2015

Direct-acting antiviral agents for the treatment of hepatitis C infection are revolutionizing how we treat patients.  What is the hype all about? Are these medications worth it?  Our panelists critically examine the results of the ION2 Study, providing insights on these questions and more.

Comments: 0
Jun 28, 2014

This is a brief review of the CANTATA-SU trial and a discussion about the role of sodium glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.

Are medications in this new class of agents something we should consider earlier in the treatment of type 2 diabetes?  Or perhaps even for the treatment of type 1 diabetes?  Are you concerned about their adverse effects and long-term safety?  Tell us what you think by posting a comment.

Comments: 1
Mar 27, 2013

The CONQUER study was double-blind, placebo-controlled clinical trial that examined the potential benefits of the combination product Qsymia (phenterimine and topiramate) in patients who were overweight and obese.  Our moderator and panelists explore the findings of this study and how this new information should be applied to practice.

Tell us what you think?  Given safety concerns that have resulted in restrictions in its prescribing and dispensing, when should...

Comments: 0
Feb 18, 2013

The PrimoTinA - asthma studies are two replicate double-blind clinical trials examining the benefits of adding inhaled  tiotropium to standard asthma therapies in patients who have not achieved optimal control.  Our moderator and panelists explore the findings of this study and how this new information should be applied to practice.

Comments: 1
Jun 15, 2011

In the landmark ACCOMPLISH trial, investigators examined whether one combination (ACEI plus thiazide) is better than another (ACEI plus CCB) for the treatment of HTN.

... Comments: 0
Nov 5, 2010

The ARBITER-6 HALTS study examined the benefits of statin add-on therapy with either ezetimibe or niacin. Although not intended to be an outcome study, a significant difference between exetimibe and niacin in terms of cardiovascular events was observed in this study. How much weight should we give to this surprising finding?

Comments: 0
Apr 18, 2010

The primary study (glycemia) in the ACCORD trial was terminated early after concerns emerged regarding the safety of a very aggressive treatment strategy.  This landmark trial has led many to re-examine the risks and benefits of intensive glycemic control in patients with type 2 diabetes. 

Comments: 6